Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Locally Advanced Breast Cancer

Breast Neoplasms, Inflammatory Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neutropenia

Triple Negative Breast Neoplasms

Early Stage Breast Cancer

Adenocarcinoma, Breast Diseases, Breast Neoplasms, Carcinoma

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neutropenia, Febrile Neutropenia

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Febrile Neutropenia

Breast Neoplasms, Neoplasms, Recurrence

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Neutropenia

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neutropenia

Breast Cancer Female

Breast Neoplasms

Breast Neoplasms, Neutropenia

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms, Neutropenia

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Breast Neoplasms, Male

Breast Neoplasms, Neutropenia

Breast Neoplasms

Clinical Trials

EMEG-ECDD

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

REaCT-OGF

BREASTIMMU02

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

NeoPACT

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

IMpassion031

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

ADVANCE

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Efficacy and Safety Study With MYL-1401H and Neulasta

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

ddTC

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Various G-CSF Regimens to Prevent Infection During Chemotherapy

A Study of LY2523355 in Participants With Breast Cancer

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

TACT2

Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients

NOLAN

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

PROTECT-1

Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy

PIONEER

Trial Exploring Feasibility of Densification and Optimal Sequencing of Postoperative Adjuvant Fluorouracil, Epirubicin Plus Cyclophosphamide (FEC) and Docetaxel Chemotherapy in Patients With High Risk Primary Operable Breast Cancer

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer